Athersys (NASDAQ:ATHX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a research report report published on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

The firm has a market cap of $833,000.00, a P/E ratio of -0.01 and a beta of -0.90. Athersys has a twelve month low of $0.01 and a twelve month high of $1.99.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.